Aspen Neuroscience, Inc., is a development stage, private biotechnology company that uses innovative genomic approaches combined with stem cell biology to deliver patient-specific, restorative cell therapies that modify the course of Parkinson disease. Aspen's therapies are based upon the scientific work of world-renowned stem cell scientist, Dr. Jeanne Loring, who has developed a novel method for autologous neuron replacement.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 04/01/20 | $70,000,000 | Series A |
ARCH Venture Partners Domain Associates Frazier Healthcare Partners OrbiMed Advisors  Sam Altman | undisclosed |
| 11/20/25 | $115,000,000 | Series C |
ARCH Venture Partners Axon Ventures Balyasny Asset Management Cormorant Asset Management Frazier Life Sciences Kite LifeForce Capital LYFE Capital Medical Excellence Capital OrbiMed Advisors Prebys Ventures Fund Revelation Partners S32 | undisclosed |
